Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
Kondo T, Fujioka M, Fujisawa S, Sato K, Tsuda M, Miyagishima T, Mori A, Iwasaki H, Kakinoki Y, Yamamoto S, Haseyama Y, Ando S, Shindo M, Ota S, Kurosawa M, Ohba Y, Teshima T; North Japan Hematology Study Group (NJHSG). Kondo T, et al. Among authors: yamamoto s. Int J Hematol. 2019 Oct;110(4):482-489. doi: 10.1007/s12185-019-02696-w. Epub 2019 Jun 25. Int J Hematol. 2019. PMID: 31240558 Clinical Trial.
Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Shigematsu A, et al. Among authors: yamamoto s. Biol Blood Marrow Transplant. 2008 May;14(5):568-75. doi: 10.1016/j.bbmt.2008.02.018. Biol Blood Marrow Transplant. 2008. PMID: 18410899 Free article.
Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Shigematsu A, et al. Among authors: yamamoto s. Biol Blood Marrow Transplant. 2009 Jun;15(6):679-85. doi: 10.1016/j.bbmt.2009.02.006. Epub 2009 Apr 11. Biol Blood Marrow Transplant. 2009. PMID: 19450752 Free article.
Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.
Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo T, Nishio M, Sato N, Tanaka J, Hashino S, Koike T, Asaka M, Imamura M. Kondo T, et al. Among authors: yamamoto s. Int J Hematol. 2010 Mar;91(2):310-21. doi: 10.1007/s12185-009-0487-y. Epub 2010 Jan 20. Int J Hematol. 2010. PMID: 20087795 Free article.
Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
Takahata M, Hashino S, Okada K, Onozawa M, Kahata K, Sugita J, Shigematsu A, Kondo T, Yamamoto S, Endo T, Nishio M, Ito YM, Tanaka J, Koike T, Asaka M, Imamura M. Takahata M, et al. Among authors: yamamoto s. Am J Hematol. 2010 Apr;85(4):243-8. doi: 10.1002/ajh.21630. Am J Hematol. 2010. PMID: 20162540 Free article.
Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies.
Kurosawa M, Yonezumi M, Hashino S, Tanaka J, Nishio M, Kaneda M, Ota S, Koda K, Suzuki N, Yoshida M, Hirayama Y, Takimoto R, Torimoto Y, Mori A, Takahashi T, Iizuka S, Ishida T, Kobayashi R, Oda T, Sakai H, Yamamoto S, Takahashi F, Fukuhara T. Kurosawa M, et al. Among authors: yamamoto s. Int J Hematol. 2012 Dec;96(6):748-57. doi: 10.1007/s12185-012-1210-y. Epub 2012 Oct 31. Int J Hematol. 2012. PMID: 23111539
A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group.
Torimoto Y, Sato K, Ikuta K, Hayashi T, Hirayama Y, Inamura J, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Mori A, Ota S, Sakai H, Shigematsu A, Shindo M, Shinzaki H, Takahashi F, Takimoto R, Tanaka J, Yamamoto S, Kohgo Y, Fukuhara T. Torimoto Y, et al. Among authors: yamamoto s. Int J Hematol. 2013 Aug;98(2):171-8. doi: 10.1007/s12185-013-1383-z. Epub 2013 Jun 29. Int J Hematol. 2013. PMID: 23813410 Clinical Trial.
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.
Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K. Takahashi N, et al. Among authors: yamamoto s. Biomark Res. 2014 Mar 20;2(1):6. doi: 10.1186/2050-7771-2-6. Biomark Res. 2014. PMID: 24650752 Free PMC article.
Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
Hirayama Y, Ishitani K, Ota S, Kurosawa M, Kondo T, Takimoto R, Mori A, Sakai H, Torimoto Y, Yamamoto S, Sato K, Iwasaki H, Kohda K, Ishida T, Kakinoki Y, Fukuhara T, Kato J. Hirayama Y, et al. Among authors: yamamoto s. Int J Hematol. 2014 Sep;100(3):281-9. doi: 10.1007/s12185-014-1629-4. Epub 2014 Jul 23. Int J Hematol. 2014. PMID: 25052874
10,617 results
You have reached the last available page of results. Please see the User Guide for more information.